Spero Therapeutics Inc (SPRO)

May 28, 2025, 11:24 AM EDT - 1 day ago

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?

GSK

May 28, 2025, 7:00 AM EDT - 1 day ago

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

GSK

May 13, 2025, 4:01 PM EDT - 16 days ago

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

May 5, 2025, 8:00 AM EDT - 24 days ago

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

Apr 28, 2025, 4:01 PM EDT - 4 weeks ago

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

Mar 27, 2025, 8:31 PM EDT - 2 months ago

Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:01 PM EDT - 2 months ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

Mar 18, 2025, 8:00 AM EDT - 2 months ago

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

Feb 25, 2025, 10:15 AM EST - 3 months ago

UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 7:00 AM EST - 3 months ago

Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Jan 19, 2025, 8:00 AM EST - 4 months ago

Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal

Jan 10, 2025, 7:00 AM EST - 4 months ago

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

Nov 14, 2024, 4:05 PM EST - 7 months ago

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

Oct 16, 2024, 4:05 PM EDT - 8 months ago

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

Oct 2, 2024, 4:30 PM EDT - 8 months ago

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

Aug 9, 2024, 10:47 AM EDT - 10 months ago

Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:01 PM EDT - 10 months ago

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

Jul 29, 2024, 4:05 PM EDT - 10 months ago

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

Jul 3, 2024, 1:05 PM EDT - 11 months ago

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 16, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

May 15, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

May 8, 2024, 8:00 AM EDT - 1 year ago

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

May 1, 2024, 4:07 PM EDT - 1 year ago

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 23, 2024, 11:37 AM EDT - 1 year ago

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Mar 13, 2024, 5:45 PM EDT - 1 year ago

Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 4:01 PM EDT - 1 year ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

Mar 6, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

Feb 28, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

Feb 26, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference

Jan 5, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics Provides Corporate Update and 2024 Outlook

Jan 2, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Nov 13, 2023, 7:05 PM EST - 1 year ago

Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 8:05 AM EST - 1 year ago

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Nov 1, 2023, 8:05 AM EDT - 1 year ago

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

Sep 20, 2023, 4:05 PM EDT - 1 year ago

Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference

Sep 6, 2023, 8:05 AM EDT - 1 year ago

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 8:05 AM EDT - 1 year ago

Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Jul 31, 2023, 8:05 AM EDT - 1 year ago

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

Jul 5, 2023, 3:06 PM EDT - 2 years ago

Spero Therapeutics: The Multi-Asset Pipeline Could Outpace The Tebipenem HBr Deal With GSK

Jun 14, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

May 11, 2023, 8:59 PM EDT - 2 years ago

Spero Therapeutics, Inc. (SPRO) Q1 2023 Earnings Call Transcript

May 11, 2023, 4:05 PM EDT - 2 years ago

Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update

May 4, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

Apr 26, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Present at Upcoming Investor Conference

Apr 21, 2023, 4:46 PM EDT - 2 years ago

Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The Market

Apr 14, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

Mar 30, 2023, 10:11 PM EDT - 2 years ago

Spero Therapeutics, Inc. (SPRO) Q4 2022 Earnings Call Transcript

Mar 30, 2023, 4:05 PM EDT - 2 years ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update